Frost & Sullivan

Report: Global stem cell market to reach $118B by 2018

Wednesday, December 3, 2014 01:02 PM

The global stem cell market earned revenues of $40.01 billion in 2013 and is estimated to nearly triple to $117.66 billion in 2018 at a compound annual growth rate (CAGR) of 24.1%, according to a new analysis from Frost & Sullivan. The study covers human adult and embryonic stem cells. While North America is the market leader with more than half of the global stem cell market share, Asia-Pacific is expected to record the highest CAGR during the forecast period. In fact, the APAC stem cell market, which was valued at $5.6 billion in 2013, is projected to increase to $18.71 billion by 2018.

More... »

Frost & Sullivan honors Clinical Ink for eSource platform that streamlines clinical development

Friday, September 5, 2014 10:56 AM

Based on its recent analysis of the eClinical solutions market, Frost & Sullivan recognizes Clinical Ink with the 2014 North American eClinical Solutions Award for Entrepreneurial Company of the Year. The award recognizes Clinical Ink's innovative SureSource platform—the first purpose-built eSource solution that captures data electronically at the point of care.

More... »

Report: Drug developers drawn to orphan drugs market, create competitive pipelines

Friday, March 28, 2014 03:08 PM

New analysis from Frost & Sullivan's Product and Pipeline Assessment of the Global Orphan Drugs Market identifies rare cancers as the orphan therapeutic area with the highest level of drug development activity. Other disease areas witnessing considerable drug development activity include blood/lymphatic system diseases, infectious/parasitic diseases, neurological diseases, metabolic diseases and immunological/inflammatory diseases.

More... »

Report: Latin American diabetes therapeutics market to transform

Wednesday, February 19, 2014 01:27 PM

The Latin American diabetes therapeutics market will experience major changes within the next three years due to the launch of innovative drugs that include three long-acting insulins and four non-insulin treatments. Nevertheless, pharmaceutical companies should continue their research to develop treatments that can restore beta-cell function and thereby postpone or prevent disease progression—areas that even newer therapies do not address.

More... »

Frost & Sullivan predict growth in mHealth, cloud computing and regulatory environment

Wednesday, December 4, 2013 12:53 PM

Frost & Sullivan has made its three big predictions for the global healthcare market. Based on a 2013 Search for Growth survey of 1,835 executives in more than 40 countries, Frost & Sullivan have said key areas of growth in 2014 and beyond will be in mHealth, cloud computing and regulatory environments.

More... »

SIRO Clinpharm named Indian CRO of the Year 2012

Monday, October 1, 2012 09:20 AM

SIRO Clinpharm, a drug development solutions provider, has been awarded the 'Indian CRO of the Year 2012' by Frost & Sullivan, a global growth partnership and consulting firm.

More... »

Radiant Sage receives Customer Value Enhancement Award from Frost & Sullivan

Monday, August 20, 2012 03:27 PM

Radiant Sage, a provider of on-demand clinical trial image management solutions based in Belmont, Mass., has received the Frost & Sullivan 2012 Customer Value Enhancement Award for its clinical trial image management solutions.

More... »

India CRO market to earn $1B by 2016, says Frost & Sullivan

Monday, August 20, 2012 09:44 AM

The CRO market in India earned revenues of $485 million in 2010-11 and is estimated to cross $1.0 billion in 2016, according to new analysis from Frost & Sullivan, “Strategic Analysis of the Clinical Research Organization Market in India.”

More... »

CMO revenue could double in Europe, says Frost & Sullivan

Thursday, May 31, 2012 03:10 PM

New analysis from Frost & Sullivan, "European Pharmaceutical and Biotech Contract Manufacturing Markets," finds that the European pharmaceutical contract manufacturing market earned revenues of $10.02 billion in 2011 and estimates this to reach $20.75 billion in 2018. Over the same period, the European biotech contract manufacturing market is set to expand from $1.21 billion to an estimated $2.67 billion.

More... »

Analysis: U.S. CMO market reviving, offering preclinical services

Tuesday, April 10, 2012 11:27 AM

The upturn in the fortunes of pharmaceutical companies after the recession is mirrored by the U.S. contract manufacturing outsourcing (CMO) market, which is expected to grow at a compound annual growth rate of 8.3% from 2011 to 2016, according to Frost & Sullivan's newest analysis of the U.S. CMO market.

More... »

CenterWatch Data Library



Browse by:


December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs